KRAS and non-small cell lung carcinoma: This review aims to summarize the clinical studies that have elucidated the potential implications of SMARCA4 mutations and SMARCA4/KRAS co-mutations on survival outcomes when treating metastatic NSCLC patients across various treatments (i.e., chemotherapy and immune checkpoint inhibitors).